Kaitlyn D’Onofrio

DocwireNews

The prognosis for high-risk (HR) chronic lymphocytic leukemia (CLL) is poor. Clinical data have found that small molecular inhibitor (SMI) therapies outperform chemoimmunotherapy (CIT) in patients with CLL, but CIT is still often chosen for HR and non-HR patients with CLL in real-world practice. A study assessing treatment patterns and time to next treatment (TTNT) in HR and non-HR patients with CLL undergoing ibrutinib (IBR) or CIT as first-line therapy was presented at the 62nd ASH Annual Meeting &amp; Exposition.
Medical records for adult HR and non-HR patients with CLL were obtained from 40 clinical practices (68% community and 32% academic). All patients initiated first-line single-agent IBR or CIT (index date) between February 14, 2014, and December 31, 2016. Patients with del(17p), del(11q), TP53 mutation, unmutated immunoglobulin heavy chain variable, or complex karyotype (≥3 chromosomal abnormalities) at the time of first-line treatment initiation were considered HR. Patients with testing-confirmed absence of the HR-associated factors were considered non-HR. To evaluate TTNT, Kaplan-Meier (KM) and Cox-proportional hazards regression analyses were implemented to compare IBR HR versus CIT HR, CIT HR versus CIT non-HR, and IBR HR versus IBR non-HR. Inverse probability treatment weighting was used to level out baseline characteristics between the two HR groups.
Final analysis consisted of 516 CLL patients, of whom 271 were HR (IBR, n=175; CIT, n=96) and 245 were non-HR (IBR, n=82; CIT, n=163).
When assessing the HR patients, the median duration of first-line therapy for the IBR patients was 28.6 months (range, 1-58.1 months) versus 5.5 months (range, 0.5-38.4 months) for the CIT patients; median follow-up duration was 33.3 months (range, 1.4-58.5 months) and 35.3 months (range, 1.3-59.5 months), respectively.
Upon KM analysis, median TTNT was significantly longer for the weighted IBR HR patients compared with CIT HR patients; they were also 54% less likely to initiate a new treatment (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.34-0.62; P&lt;0.01).
When comparing HR versus non-HR patients who received CIT, HR patients had a much shorter median TTNT and were more than twice as likely to start a new treatment (HR, 2.43; 95% CI, 1.58-3.47; P&lt;0.01). TTNT did not largely differ between the IBR HR versus non-HR patients (median TTNT not reach; HR, 2.2; 95% CI, 0.96-4.96; P=0.06).
When assessing the available follow-up, weighted IBR HR patients, compared with weighted CIT HR patients, were more likely to have only had one line of treatment (74.7% vs. 47.2%), as were CIT non-HR patients compared with CIT HR patients (69.9% vs. 45.8%) and IBR non-HR patients versus IBR HR patients (91.5% vs. 81.7%). Most patients received SMI therapy as second-line treatment.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Real-World Data on First-Line Ibrutinib or Chemoimmunotherapy Outcomes in CLL By Risk Status

ASH Annual Meeting 2020

The prognosis for high-risk (HR) chronic lymphocytic leukemia (CLL) is poor. Clinical data have found that small molecular inhibitor (SMI) therapies outperform ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe